Skip to main content

Table 5 MMRM and LOCF_ANCOVA analyses of HAMD17 total score in Studies 1 and 2.

From: The efficacy of duloxetine: A comprehensive summary of results from MMRM and LOCF_ANCOVA in eight clinical trials

   STUDY 1 STUDY 2
MMRM
THERAPY Week N Mean change Std.error p-value N Mean change Std.error p-value
DULOX 1 121 -2.89 0.36 .435 123 -2.89 0.38 .601
PLACEBO 1 115 -2.50 0.37   136 -2.64 0.36  
DULOX 2 112 -5.72 0.49 < .001 109 -5.54 0.48 .071
PLACEBO 2 110 -3.39 0.50   129 -4.43 0.45  
DULOX 3 105 -7.37 0.53 < .001 108 -6.82 0.55 .287
PLACEBO 3 103 -4.58 0.54   122 -6.06 0.52  
DULOX 5 100 -8.76 0.60 < .001 98 -8.58 0.66 .116
PLACEBO 5 101 -5.74 0.60   111 -7.20 0.62  
DULOX 7 91 -9.93 0.64 < .001 89 -10.14 0.69 .008
PLACEBO 7 93 -5.82 0.65   97 -7.69 0.65  
DULOX 9 84 -10.91 0.70 < .001 81 -10.46 0.71 .024
PLACEBO 9 89 -6.05 0.69   90 -8.29 0.67  
LOCF_ANCOVA
DULOX LOCF_ANCOVA 121 -9.47 0.63 < .001 123 -8.75 0.71 .048
PLACEBO LOCF_ANCOVA 115 -5.67 0.66   136 -7.02 0.68